Efficacy of fusion peptide homologs in blocking cell lysis and HIV- induced fusion

AIDS Research and Human Retroviruses

Volumn 14, Issue 5, 1998, Pages 385-392

  Silburn, Katherine A ^a   Mcphee, Dale A ^a   Maerz, Anne L ^b   Poumbourios, Pantelis ^b   Whittaker, Robert G ^c   Kirkpatrick, Alan ^c   Reilly, Wayne G ^c   Manthey, Michael K ^c   Curtain, Cyril C ^c  

^a MACFARLANE BURNET INSTITUTE FOR MEDICAL RESEARCH AND PUBLIC HEALTH   (Australia)

^b ST VINCENT'S INSTITUTE OF MEDICAL RESEARCH   (Australia)

^c CSIRO   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; GLYCOPROTEIN GP 41; HYBRID PROTEIN; PHENYLALANINE;

AMINO TERMINAL SEQUENCE; ARTICLE; CYTOLYSIS; GENE FUSION; HUMAN IMMUNODEFICIENCY VIRUS; MOLECULAR WEIGHT; NONHUMAN; PEPTIDE ANALYSIS; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN STRUCTURE;

EID: 0032549632     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.1998.14.385     Document Type: Article

References (34)

1. Owens RJ, Tanner C, Srinivas RV, Ananthramaiah GM, Kahlon JB, Segrest JP, and Compans RW: Oligopeptide inhibitors of HIV-induced syncytium formation. AIDS Res Hum Retroviruses 1990;6:1289-1295.
2. Slepushkin VA, Kornilaeva GV, Andreev SM, Sidorova MS, Petrukhina AO, Matsevich GR, Raduk SV, Grigoriev VB, Makarova TV, Lukashov VV, and Karamov EV: Inhibition of human immunodeficiency virus type 1 (HIV-1): Penetration into target cells by synthetic peptides mimicking the N-terminus of the HIV-1 transmembrane glycoprotein. Virology 1993;194:294-301.
3. Gallaher WR, Henderson LA, Fermin CD, Montelaro RC, Martin A, Qureshi MN, Ball JM, Sattentau Q, Luo-Zhang H, and Garry RF: Membrane interactions of human immunodeficiency virus: Attachment, fusion and cytopathology. Adv Membrane Fluid 1992;6:113-142.
4. Felser J, Klimkait T, and Silver J: A syncytia assay for human immunodeficiency virus type-I (HIV-I) envelope protein and its use in studying HIV-I mutations. Virology 1989;170:566-570.
5. Freed EO, Myers DJ, and Risser R: Characterization of the fusion domain of the human immunodeficiency virus type 1 envelope glycoprotein gp41. Proc Natl Acad Sci USA 1990;87:4650-4654.
6. Rafalski M, Lear JD, and DeGrado WF: Phospholipid interactions of synthetic peptides representing the N-terminus of HIV-gp41. Biochemistry 1990;9:7917-7922.
7. Nieva JL, Nir S, Muga A, Goni FM, and Wilschut J: Interaction of the HIV-1 fusion peptide with phospholipid vesicles: Different structural requirements for fusion and leakage. Biochemistry 1994;29:7917-7922.
8. + lymphocytes. Biochim Biophys Acta 1992;1139:251-256.
9. Mobley PW, Lee H-F, Curtain CC, Kirkpatrick A, Waring AJ, and Gordon LM: The amino-terminal peptide of HIV-1 glycoprotein fuses human erythrocytes. Biochim Biophys Acta 1995;1271: 304-314.
10. Gordon LM, Waring AJ, Curtain CC, Kirkpatrick A, Leung C, Faull K, and Mobley PW: Antivirals that target the amino-terminal domain of HIV type 1 glycoprotein 41. AIDS Res Hum Retroviruses 1995;11:667-686.
11. Myers G, Korber B, Hahn BH, Jeang K-T, Mellors JW, McCutchan FE, Henderson LE, and Pavlakis GN (eds.): Human Retroviruses and AIDS 1995: A Compilation and Analysis of Nucleic Acid and Amino Acid Sequences. Los Alamos National Laboratory. Los Alamos, New Mexico, 1995, p. II-A-109.
12. Gordon LM, Curtain CC, Zhong YC, Kirkpatrick A, Mobley PW, and Waring AJ: The amino terminal peptide of HIV-1 glycoprotein 41 interacts with human erythrocyte membranes: Peptide confermation, orientation and aggregation. Biochim Biophys Acta 1992;1139:257-274.
13. Singh J and Thornton JM: Atlas of Protein Side-Chain Interactions 1991. IRL Press (Oxford University Press), Oxford, 1991.
14. Bodanszky M and Bodanszky A: In: The Practice of Peptide Synthesis. (Hafner K, Lehn J-M, Rees CW, von Raqué Schleyer P, Trost BM, and Zahradnik R, eds.). Springer-Verlag, Berlin, 1984, p. 125.
15. Whittaker RG, Hayes PJ, and Bender VJ: A gentle method for linking TRIS to amino acids and peptides. Peptide Res 1993;6: 125-128.
16. Op den Kamp JF: Lipid asymmetry in membranes. Annu Rev Biochem 1979;48:47-71.
17. Miyoshi I, Kubonishi I, Yoshimoto S, Akagi T, Ohtsuki Y, Shiraishi Y, Nagata K, and Himuna Y: Type C virus particles in a cord T-cell line derived by cocultivating normal cord leukocytes and human leukaemic T-cells. Nature (London) 1981;294:770-771.
18. Kieman R, Marshall J, Bowers R, Doherty RR, and McPhee DA: Kinetics of HIV-1 replication and intracellular accumulation of particles in HTLV-1 transformed cells. AIDS Res Hum Retroviruses 1990;6:743-752.
19. Kiernan RE, McPhee DA, and Doherty RR: Quantitation of infectious human immunodeficiency virus using a modified plaque forming assay. J Virol Methods 1988;22:303-308.
20. Li P and Burrell C: Synthesis of human immunodeficiency virus DNA in a cell-to-cell transmission model. AIDS Res Hum Retroviruses 1992;8:253-259.
21. Hansen MB, Nielson SE, and Berg K: Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell killing. J Immunol Methods 1989;119:203-210.
22. Mitsuya H and Broder S: Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotrophic virus type III/ lymphadenopathy-associated virus (HTLV-III/LAV) by 2′,3′-dideoxynucleosides. Proc Natl Acad Sci USA 1986;83:1911-1915.
23. Fecondo JV, Pavuk NC, Silburn KA, Read DMY, Mansell AS, Boyd AW, and McPhee DA: Synthetic peptide analogs of intercellular adhesion molecule 1 (ICAM-1) inhibit HIV-1 replication in MT-2 cells. AIDS Res Hum Retroviruses 1993;9:733-740.
24. Willey RL, Smith DH, Lasky LA, Theodore TS, Earl PL, Moss B, Capon DJ, and Martin MA: In vitro mutagenesis identifies a region within the envelope gene of the human immunodeficiency virus that is critical for infectivity. J Virol 1988;62:139-147.
25. Maddon PJ, Dalgleish AG, McDougal JS, Clapham PR, Weiss RA, and Axel R: The T4 gene encodes the AIDS virus receptor and is expressed in the immune system and the brain. Cell 1986;47: 333-348.
26. Earl PL, Doms RW, and Moss B: Oligomeric structure of the human immunodeficiency virus type 1 envelope glycoprotein. Proc Natl Acad Sci USA 1990;87:648-652.
27. Dubai JW, Roberts SJ, Brody B, and Hunter E: Mutations in the leucine zipper of the human immunodeficiency virus type 1 transmembrane glycoprotein affect fusion and infectivity. J Virol 1992;66:6616-6625.
28. Owens RJ, Anantharamaiah GM, Kahlon JB, Srinivas RV, Compans RW, and Segrest JP: Apolipoprotein A-1 and its amphipathic helix peptide analogues inhibit human immunodeficiency virus-induced syncytium formation. J Clin Invest 1990;86:1142-1150.
29. Gordon LM, Curtain CC, McCloyn V, Kirkpatrick A, Mobley PW, and Waring AJ: The amino terminal peptide of HIV-1 gp41 interacts with human serum albumin. AIDS Res Hum Retroviruses 1993;9:1145-1156.
30. Dimitrov DS, Broder CC, Berger EA, and Blumenthal R: Calcium ions are required for cell fusion mediated by the CD4-human immunodeficiency virus type 1 envelope glycoprotein interaction. J Virol 1993;67:1647-1652.
31. Martin I, Dubois M-C, Saermark T, and Ruysschaert J-M: Apolipoprotein A-1 interacts with the N-terminal fusogenic domains of SIV (simian immunodeficiency virus) gp32 and HIV (human immunodeficiency virus) gp41: Implications in viral entry. Biochim Biophys Res Commun 1992;186:95-101.
32. Callahan L: HIV-1 virion-cell interactions; an electrostatic model of pathogenicity and syncytium formation. AIDS 1994;10: 231-233.
33. Schols D, Pauwels R, Desmyter J, and De Clerq E: Dextran sulphate and other polyanionic anti-HIV compounds specifically interact with the viral gp120 glycoprotein expressed by T-cells infected with HIV-1. Virology 1990;175:556-561.
34. Lu M, Blacklow SC, and Kim PS: A trimeric structural domain of the HIV-1 transmembrane glycoprotein. Nature Struct Biol 1995;2:1075-1082.